PharmaMar Seeks EU Approval for Aplidin to Treat Multiple Myeloma
PharmaMar has submitted a Marketing Authorization Application (MAA) to the …
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read morePharmaMar has submitted a Marketing Authorization Application (MAA) to the …
The Multiple Myeloma Research Foundation (MMRF) and the…
The association between excess body fat and increased risk…
Minimal residual disease, a measurement that shows a low…
Janssen Biotech has submitted a supplemental Biologics License…
Patients with heavily treated multiple myeloma have promising response…